NCT03670888View on ClinicalTrials.gov

A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

November 16, 2018

Primary Completion Date

March 19, 2019

Study Completion Date

March 19, 2019

Conditions
B Cell Lymphoma
Interventions
BIOLOGICAL

JHL1101

100 mg/10 mL solution in a single-use vial

BIOLOGICAL

Rituximab

100 mg/10 mL solution in a single-use vial

Trial Locations (2)

Unknown

First Hospital of Shanxi Medical University, Taiyuan

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

Sponsors

Lead Sponsor

JHL Biotech, Inc.
All Listed Sponsors
lead

JHL Biotech, Inc.

INDUSTRY